Cerebrospinal fluid somatostatin in West syndrome: Changes in response to combined treatment with high-dose pyridoxal phosphate and low-dose corticotropin

Neuropeptides

Volumn 32, Issue 6, 1998, Pages 581-586

  Hirai, K ^a,b   Seki, T ^a   Takuma, Y ^a  

^a KEIO UNIVERSITY   (Japan)

^b Shimada Ryouiku Centre   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; CORTICOTROPIN; PYRIDOXAL 5 PHOSPHATE; SOMATOSTATIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CEREBROSPINAL FLUID LEVEL; EPILEPSY; FEMALE; HUMAN; INFANT; MALE; NERVE EXCITABILITY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SEIZURE; WEST SYNDROME;

EID: 0032406627     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0143-4179(98)90089-0     Document Type: Article

References (32)

1. Riekkinen P J, Pitkanen A. Somatostatin and epilepsy. Metabolism 1990; 39: 112-115.
2. Seki T. Combination treatment of high-dose pyridoxal phosphate and low-dose ACTH in children with West syndrome and related disorders. Jpn J Psychiatr Neurol 1990; 44: 219-237.
3. Takuma Y, Seki T. Combination therapy of infantile spasms with high-dose pyridoxal phosphate and low-dose corticotropin. J Child Neurol. 1996; 11: 35-40.
4. Ohtsuka Y, Matsuda M, Ogino T, Kobayashi K, Ohtahara S. Treatment of the West syndrome with high-dose pyridoxal phosphate. Brain Dev 1987; 9: 418-421.
5. Beal M F, Mazurek M F, Black P M, Martin J B. Human cerebrospinal fluid somatostatin in neurologic disease. J Neurol Sci 1985; 71: 91-104.
6. Arimura A, Lundqvist G, Rothman J, et al. Radioimmunoassay of somatostatin. Metabolism 1978; 27: 1139-1144.
7. Geola F L, Yamada T, Warwick R J et al. Regional distribution of somatostatin-like immunoreactivity in the human brain. Brain Res 1981; 229: 35-42.
8. Sloviter R S. Decreased hippocampal inhibition and a selective loss of interneurons in experimental epilepsy. Science 1987; 235: 73-76.
9. Pitkanen A, Beal M F, Sirvio J et al. Somatostatin, neuropeptide Y, GABA and cholinergic enzymes in brain of pentylenetetrazol-kindled rats. Neuropeptides 1989; 14: 197-207
10. Schwarzer C, Williamson J M, Lothman E W et al. Somatostastin, neuropeptide Y, neurokinin B and cholecystokinin immunoreactivity in two chronic models of temporal lobe epilepsy. Neuroscience 1995; 69: 831-845.
11. Atack J R, Beal M F, May C et al. Cerebrospinal fluid somatostatin and neuropeptide Y. Arch Neurol 1988; 45: 269-274.
12. Hartikainen P, Soininen H, Reinkainen K J et al. Neurotransmitter markers in the cerebrospinal fluid of normal subjects. Effects of aging and other confounding factors. J Neural Transm Gen Sect 1991; 84: 103-117.
13. Maeda K, Yasuda M, Kaneda H et al. Cerebrospinal fluid (CSF) neuropeptide Y and somatostatin-like immunoreactivities in man. Neuropeptides 1994; 27: 323-332.
14. Lang S, Peigen K, Liu J et al. Somatostatin concentrations in cerebrospinal fluid and brain tissue of patients with refractory epilepsy. Mol Chem Neuropathol 1992; 17: 239-247
15. Pranzatelli M R. Putative neurotransmitter abnormalities in infantile spasms: Cerebrospinal fluid neurochemistry and drug effects. J Child Neurol 1994; 9: 119-129.
16. Lundqvist G, Gustavsson S, Elde R, Arimura A. A radioimmunoabsorbent assay for plasma somatostatin. Clin Chim Acta 1980; 101: 183-191.
17. Nagaki S, Fukuyama Y, Kato N. Immunoreactive somatostatin contents in the cerebrospinal fluid of children with various types of epilepsy. Jpn J Psychiatr Neurol 1988; 42: 651-652.
18. Patel Y C, Rao K, Reichlin S. Somatostatin in human cerebrospinal fluid. N Engl J Med 1977; 296: 529-533.
19. Jolkkonen J, Kahkonen K, Pitkanen A. Cholinergic deafferentation exacerbates seizure-induced loss of somatostatin-immunoreactive neurons in the rat hippocampus. Neuroscience 1997; 80: 401-411.
20. Jolkkonen J, Jolkkonen E, Pitkanen A. Seizure-induced damage to somatostatin-immunoreactive neurons in the rat hippocampus is regulated by fimbria-fornix transection. Exp Neurol 1997; 145: 141-153.
21. Tuunanen J, Halonen T, Pitkanen A. Decrease in somatostatinimmunoreactive neurons in the rat amygdaloid complex in a kindling model of temporal lobe epilepsy. Epilepsy Res 1997; 26:315-327
22. Mitchell J, Gatherer M, Sundstrom L E. Loss of hilar somatostatin neurons following tetanus toxin-induced seizures. Acta Neuropathol (Berl) 1995; 89: 425-430.
23. Dalby N O, Tonder N, Wolby D P D et al. No loss of hippocampal hilar somatostatinergic neurons after repeated electroconvulsive shock: A combined stereological and in situ hybridization study. Biol Psychiatry 1996; 40: 54-60.
24. Rissler K, Jost S, Mohadjer M et al. Molecular size distribution of somatostatin-like immunoreactivity in the cerebroventricular fluid of neurosurgical patients. Neurosci Res 1987; 4: 343-356.
25. Pitkanen A, Jolkkonen J, Riekkinen P. β-endorphin, somatostatin, and prolactin levels in cerebrospinal fluid of epileptic patients after generalized convulsion. J Neurol Neurosurg Psychiatry 1987; 50: 1294-1297
26. Devinsky O, Emoto S, Nadi N S, Theodore W H. Cerebrospinal fluid levels of neuropeptides, cortisol, and amino acids in patients with epilepsy. Epilepsia 1993; 34: 255-261.
27. Wolkowitz O M, Rubinow D R, Breier A et al. Prednisone decreases CSF somatostatin in healthy humans: Implications for neuropsychiatric illness. Life Sci 1987; 41: 1929-1933.
28. Serby M, Richardson S B, Rypma B et al. Somatostatin regulation of the CRF-ACTH-cortisol axis. Biol Psychiatry 1986; 21: 971-974.
29. Pitkanen A, Hyttinen J M, Sirvio J et al. The levels of somatostatin in the brain and CSF of rat after carbamazepine administration. Pharmacol Toxicol. 1989; 64: 266-271.
30. Pitkanen A, Lepola U, Ylinen A, Riekkinen P J. Somatostatin and β-endorphin levels in cerebrospinal fluid of nonmedicated and medicated patients with epileptic seizures. Neuropeptides 1989; 13: 9-15.
31. Steardo L, Barone P, Hunnicutt E. Carbamazepine lowering effect on CSF somatostatin-like immunoreactivity in temporal lobe epileptics. Acta Neurol Scand 1986; 74: 140-144.
32. Riekkinen P J, Pitkanen A, Ylinen A et al. Specificity of vigabatrin for the GABAergic system in human epilepsy. Epilepsia 1989; 30(Suppl 3): S18-S22.